Bone Biologics Corporatio... (BBLGW)
NasdaqCM: BBLGW
· Real-Time Price · USD
3.50
+0.00 (0.00%)
At close: Aug 10, 2026, 9:44 AM
Bone Biologics Corporation (BBLGW) Stock Price, Analysis & Data
0.00% (1D)
| Bid | n/a |
| Market Cap | n/a |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -2.86M |
| Beta | 0.53 |
| EPS (ttm) | -0.14 |
| PE Ratio (ttm) | n/a |
| Forward PE | n/a |
| P/B (ttm) | 1.35 |
| P/S (ttm) | n/a |
| Earnings Date | n/a |
| Ask | n/a |
| Volume | 313 |
| Avg. Volume (20D) | 408 |
| Open | 9.97 |
| Previous Close | 3.50 |
| Day's Range | 3.50 - 5.97 |
| 52-Week Range | 3.50 - 35.95 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About BBLGW
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein in the United States. Its lead product is NELL-1/DBM medical device, an osteopromotive recombinant protein, which provides target specific control over bone regeneration. The company also develops NB1, a NELL-1/DBM fusion device for use in lumbar spinal fusion, as well as spine implants, non-union trauma cases, a...
IPO Date Oct 13, 2021
Employees 2
Stock Exchange NasdaqCM
Ticker Symbol BBLGW
Website https://www.bonebiologics.com
Financial Performance
In 2025, Bone Biologics's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -3.11M, a decrease of -24.4%.
Financial Statements
11 months ago · Associated Press Finance
BC-Most Active Stockstd class="col-issue">Next Technology Holding Inc.